Ro, headquartered in United States, remains privately held in the telehealth space. Investors last valued the company at $5B. Its shares do not trade on a public exchange.
2 valuations. The latest, $7B post-money, was set by the Series D-1 in Feb 2022.
FirstMarkLEADSShawSpring PartnersLEAD
General CatalystLEAD
FirstMark CapitalLEAD
TQ VenturesLEADFirstMarkShawSpring PartnersGeneral CatalystFirstMark CapitalRo, legally Roman Health Ventures Inc., is a New York City telehealth company that diagnoses patients and then prescribes and delivers treatment through its own labs and pharmacy across the continental United States. Zachariah Reitano, Saman Rahmanian, and Rob Schutz launched it as Roman in October 2017, treating erectile dysfunction before renaming to Ro in 2018 and expanding into weight loss, hair loss, fertility, and skincare.
Patients complete an online visit, a physician reviews it and prescribes if appropriate, and medication ships directly to their home. Ro has been used by at least one patient in every county in the United States.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Ro.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Ro availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Ro included.
The routes section explains what is realistically available for a company at this stage.
No. Ro is a private company; its shares do not trade on a public exchange.
The last valuation is $5B.
Lead investors for each round are in the funding timeline.
The closest telehealth peers are on the competitors page.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
